Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Amersfoort – page 10

119 clinical trials in Amersfoort, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Amersfoort at a glance
119
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

119 trials in Amersfoort

Open in trial search

Non-small cell lung cancer stage I+1

Not recruiting

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Infertility+2

Not recruiting

Study on Progesterone for Improving Birth Rates in Couples with Unexplained Infertility Undergoing Mild Ovarian Stimulation and Intrauterine Insemination

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Progesterone, Micronised
  • Sponsor:Universitair Medisch Centrum Utrecht

Lipoprotein metabolism disorder

Not recruiting

Study of LY3473329 for Adults with High Lipoprotein(a) Levels at Risk for Heart Problems

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:LY3473329
  • Sponsor:Eli Lilly & Co.

Colon cancer stage III+1

Not recruiting

Study on Aspirin for Preventing Recurrence and Improving Survival in Patients with Stage II and III Colon Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Leiden University Medical Center

Multiple sclerosis

Not recruiting

Study Comparing Rituximab and Ocrelizumab for Patients with Relapsing Multiple Sclerosis Starting Anti-CD20 Therapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

High-grade B-cell lymphoma

Not recruiting

Study on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Pancreatic carcinoma

Not recruiting

Study comparing FOLFIRINOX versus gemcitabine-based chemoradiotherapy in patients with resectable or borderline resectable pancreatic cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Acute myeloid leukaemia+1

Not recruiting

Study on Midostaurin and Decitabine for Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Who Are Unfit for Intensive Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Gastrooesophageal cancer

Not recruiting

Study on Liposomal Irinotecan, Carboplatin, or Oxaliplatin for First-Line Treatment in Patients with Advanced Esophagogastric Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Amersfoort

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for breast cancer, prostate cancer, and leukemia. Research encompasses targeted therapies and novel drug combinations.

  • Breast Cancer Treatment Studies
  • Prostate Cancer Interventions
  • Hematological Malignancies

Emphasis on personalized treatment approaches and improving patient outcomes through targeted therapies.

02 Cardiovascular Studies

Research initiatives exploring cardiovascular disease management and prevention, including innovative treatments for reducing major cardiovascular events and improving patient outcomes.

  • Lipid Management Studies
  • Heart Disease Prevention
  • Cardiovascular Risk Reduction

Focus on developing new therapeutic approaches for cardiac conditions and preventive strategies.

03 Neurological Disorders

Clinical investigations into dementia and related conditions, studying new approaches to manage behavioral symptoms and improve patient care outcomes.

  • Dementia Management
  • Behavioral Interventions
  • Therapeutic Approaches

Dedicated to understanding and treating complex neurological conditions with innovative therapies.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.